![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
[email protected]Shown: posts 1 to 10 of 10. This is the beginning of the thread.
Posted by Hugh on January 25, 2022, at 13:13:19
Wesana's novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a microdose of psilocybin combined with cannabidiol, significantly reduced depressive behaviors in a validated animal model
A single high dose of psilocybin alone demonstrated rapid, significant, and short acting improvement in depressive behaviors up to 14 days following administration
Following the single high dose, the maintenance regimen of a microdose of psilocybin in combination with cannabidiol resulted in an additional and sustained 64% reduction in depressive behaviors relative to the psilocybin single high dose alone
Combining psilocybin and cannabidiol, the animal study, conducted by an independent global laboratory services provider, demonstrated considerable and sustained improvement in depressive behaviors.
Wesana's novel and proprietary depression treatment protocol includes a single high dose of psilocybin followed by a maintenance regimen of a microdose of psilocybin combined with cannabidiol. In a validated preclinical animal model of depression, the maintenance regimen demonstrated up to 64% further improvement than those observed with a single high dose of psilocybin alone.
Furthermore, the maintenance regimen provided a sustained antidepressant effect after the single high dose of psilocybin. Wesana's proprietary treatment protocol is currently being evaluated for the treatment of multiple mental health conditions including major depressive disorder associated with traumatic brain injury.
"The positive results of this study align with my individual experience and the improvements that I observed in my personal journey with depression. It's thrilling to see our scientific data support Wesana's mission to find more effective treatments for the millions of individuals suffering from the symptoms of traumatic brain injury including depression," said Daniel Carcillo, Wesana founder and Chief Executive Officer.
Dr. Mark Wingertzahn, Wesana's Chief Scientific Officer, added "This is a great step forward in establishing the scientific evidence to support the utility of a combination product including psilocybin and cannabidiol in the treatment of depression and other unmet medical needs. Additionally, these data provide fundamental, independent scientific support for the ongoing drug development program for SANA-013."
About Wesana Health.
Wesana Health helps people transcend barriers in mental health and performance. We innovate in care development through our therapies and patent-pending protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model. Learn more at www.wesanahealth.com.
Posted by linkadge on January 26, 2022, at 17:19:01
In reply to Psilocybin-cannabidiol combo for depression, posted by Hugh on January 25, 2022, at 13:13:19
Interesting. However, I really wanted a 65% reduction in symptoms so I will ignore this (kidding).
I wonder what a CBD + ketamine + psilocybin combination might do :)
Actually, I have got some impressive results with CBD + agmatine. Agmatine has shown rapid acting (ketamine like) effects in animal models of depression. In my opinion, it is underutilized.
Linkadge
Posted by Hugh on January 27, 2022, at 13:34:24
In reply to Re: Psilocybin-cannabidiol combo for depression, posted by linkadge on January 26, 2022, at 17:19:01
> I wonder what a CBD + ketamine + psilocybin combination might do :)
Sounds like quite a cocktail!
> Actually, I have got some impressive results with CBD + agmatine. Agmatine has shown rapid acting (ketamine like) effects in animal models of depression. In my opinion, it is underutilized.
>
> LinkadgeGlad to hear that CBD + agmatine is helping you.
Posted by Lamdage22 on January 28, 2022, at 1:44:47
In reply to Re: Psilocybin-cannabidiol combo for depression » linkadge, posted by Hugh on January 27, 2022, at 13:34:24
Have you researched Agmatine? How safe is it? Does it do anything for anxiety? Thanks.
> > Actually, I have got some impressive results with CBD + agmatine. Agmatine has shown rapid acting (ketamine like) effects in animal models of depression. In my opinion, it is underutilized.
> >
> > Linkadge
>
> Glad to hear that CBD + agmatine is helping you.
>
>
Posted by jay2112 on January 28, 2022, at 19:55:53
In reply to Re: Psilocybin-cannabidiol combo for depression, posted by linkadge on January 26, 2022, at 17:19:01
> Interesting. However, I really wanted a 65% reduction in symptoms so I will ignore this (kidding).
>
> I wonder what a CBD + ketamine + psilocybin combination might do :)
>
> Actually, I have got some impressive results with CBD + agmatine. Agmatine has shown rapid acting (ketamine like) effects in animal models of depression. In my opinion, it is underutilized.
>
> Linkadge
>Hey Link...
I like your train of thought. :) Please tell us more about agmatine.
Jay
Posted by Hugh on January 29, 2022, at 18:17:49
In reply to Re: Psilocybin-cannabidiol combo for depression » linkadge, posted by jay2112 on January 28, 2022, at 19:55:53
I hope linkadge will chime in here, because I haven't tried agmatine, but I have been researching it since linkadge's post about it. Agmatine is an NMDA antagonist. It "site-selectively inhibits excessive NMDA activity without disrupting normal, physiological function," like ketamine can. It appears to be safe and effective.
In a pilot study, 11 patients suffering from neuropathies took agmatine daily for 8 weeks. At the end of the 8 weeks, their pain levels were reduced an average of 46%. The dose used in this pilot study was 6 445-mg agmatine sulfate capsules per day (3 capsules twice daily, or 2 capsules thrice daily with or after meals).
This 2017 thesis from the University of Minnesota has a lot of information about agmatine:
https://conservancy.umn.edu/bitstream/handle/11299/193441/Peterson_umn_0130E_18748.pdf
Posted by Lamdage22 on January 30, 2022, at 1:37:37
In reply to Re: Psilocybin-cannabidiol combo for depression, posted by Hugh on January 29, 2022, at 18:17:49
Would it worsen propensity for psychotic symptoms?
Posted by Hugh on January 30, 2022, at 15:44:27
In reply to Re: Psilocybin-cannabidiol combo for depression, posted by Lamdage22 on January 30, 2022, at 1:37:37
It doesn't appear to.
"Moreover, agmatine established GABA/glutamate balance by increasing GABA levels and decreased glutamate concentration significantly [in test subjects undergoing benzodiazepine withdrawal] (p < 0.01)."
https://bjbas.springeropen.com/articles/10.1186/s43088-021-00125-8
Posted by beckett2 on February 7, 2022, at 15:11:22
In reply to Re: Psilocybin-cannabidiol combo for depression, posted by Hugh on January 29, 2022, at 18:17:49
> I hope linkadge will chime in here, because I haven't tried agmatine, but I have been researching it since linkadge's post about it. Agmatine is an NMDA antagonist. It "site-selectively inhibits excessive NMDA activity without disrupting normal, physiological function," like ketamine can. It appears to be safe and effective.
>
> In a pilot study, 11 patients suffering from neuropathies took agmatine daily for 8 weeks. At the end of the 8 weeks, their pain levels were reduced an average of 46%. The dose used in this pilot study was 6 445-mg agmatine sulfate capsules per day (3 capsules twice daily, or 2 capsules thrice daily with or after meals).
>
> This 2017 thesis from the University of Minnesota has a lot of information about agmatine:
>
> https://conservancy.umn.edu/bitstream/handle/11299/193441/Peterson_umn_0130E_18748.pdfOn a related topic, just thought since you and link are talking about glutamate. Do you wonder if a predictor of glutamate antagonist's sucess might be a combination of patients presenting with pain and depression?
Posted by Hugh on February 10, 2022, at 13:11:42
In reply to Re: Psilocybin-cannabidiol combo for depression, posted by beckett2 on February 7, 2022, at 15:11:22
I hadn't thought of that. Could be.
> > I hope linkadge will chime in here, because I haven't tried agmatine, but I have been researching it since linkadge's post about it. Agmatine is an NMDA antagonist. It "site-selectively inhibits excessive NMDA activity without disrupting normal, physiological function," like ketamine can. It appears to be safe and effective.
> >
> > In a pilot study, 11 patients suffering from neuropathies took agmatine daily for 8 weeks. At the end of the 8 weeks, their pain levels were reduced an average of 46%. The dose used in this pilot study was 6 445-mg agmatine sulfate capsules per day (3 capsules twice daily, or 2 capsules thrice daily with or after meals).
> >
> > This 2017 thesis from the University of Minnesota has a lot of information about agmatine:
> >
> > https://conservancy.umn.edu/bitstream/handle/11299/193441/Peterson_umn_0130E_18748.pdf
>
> On a related topic, just thought since you and link are talking about glutamate. Do you wonder if a predictor of glutamate antagonist's sucess might be a combination of patients presenting with pain and depression?
>
>
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
[email protected]
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.